RSS feed

Publications by Nina Iversen

57 publications found

Original articles

Lind SM, Sletten M, Hellenes M, Mathelier A, Tekpli X, Tinholt M, Iversen N (2024)
Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy
J Thromb Haemost (in press)
DOI 10.1016/j.jtha.2024.02.008, PubMed 38382738

Tinholt M, Tekpli X, Torland LA, Tahiri A, Geisler J, Kristensen V, Sandset PM, Iversen N (2024)
The breast cancer coagulome in the tumor microenvironment and its role in prognosis and treatment response to chemotherapy
J Thromb Haemost (in press)
DOI 10.1016/j.jtha.2024.01.003, PubMed 38237862

Bassi N, Hovland HN, Rasheed K, Jarhelle E, Pedersen N, Mchaina EK, Bakkan SME, Iversen N, Høberg-Vetti H, Haukanes BI, Knappskog PM, Aukrust I, Ognedal E, Van Ghelue M (2023)
Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays
BMC Cancer, 23 (1), 368
DOI 10.1186/s12885-023-10790-w, PubMed 37085799

de la Morena-Barrio ME, Suchon P, Jacobsen EM, Iversen N, Miñano A, de la Morena-Barrio B, Bravo-Pérez C, Padilla J, Cifuentes R, Asenjo S, Deleuze JF, Trégouët DA, Lozano ML, Vicente V, Sandset PM, Morange PE, Corral J (2022)
Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays
Blood, 140 (2), 140-151
DOI 10.1182/blood.2021014708, PubMed 35486842

Andresen MS, Sletten M, Sandset PM, Iversen N, Stavik B, Tinholt M (2021)
Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells
Thromb Haemost, 122 (8), 1288-1295
DOI 10.1055/a-1707-2130, PubMed 34826880

Andersen E, Chollet ME, Sletten M, Stavik B, Skarpen E, Backe PH, Thiede B, Glosli H, Henriksson CE, Iversen N (2021)
Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding
Thromb Haemost, 121 (12), 1588-1598
DOI 10.1055/a-1450-8568, PubMed 33742435

Cui XY, Tjønnfjord GE, Kanse SM, Dahm AEA, Iversen N, Myklebust CF, Sun L, Jiang ZX, Ueland T, Campbell JJ, Ho M, Sandset PM (2021)
Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia
Sci Rep, 11 (1), 5127
DOI 10.1038/s41598-021-84695-8, PubMed 33664415

Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N (2020)
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104

Andresen MS, Stavik B, Sletten M, Tinholt M, Sandset PM, Iversen N, Skretting G (2020)
Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells
Sci Rep, 10 (1), 4036
DOI 10.1038/s41598-020-61018-x, PubMed 32132611

Skretting G, Andersen E, Myklebust CF, Sandset PM, Tinholt M, Iversen N, Stavik B (2019)
Transcription factor FOXP3: A repressor of the TFPI gene?
J Cell Biochem, 120 (8), 12924-12936
DOI 10.1002/jcb.28563, PubMed 30861202

Langerud J, Jarhelle E, Van Ghelue M, Ariansen SL, Iversen N (2018)
Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance
Hum Genomics, 12 (1), 51
DOI 10.1186/s40246-018-0183-1, PubMed 30458859

Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
J Thromb Haemost, 16 (7), 1347-1356
DOI 10.1111/jth.14151, PubMed 29766637

Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Thromb Res, 157, 111-116
DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156

Stavik B, Holm S, Espada S, Iversen N, Sporsheim B, Bjerkeli V, Dahl TB, Sandset PM, Skjelland M, Espevik T, Skretting G, Halvorsen B (2017)
Increased expression of TFPI in human carotid stenosis
Thromb Res, 155, 31-37
DOI 10.1016/j.thromres.2017.04.024, PubMed 28482260

Andresen MS, Ali HO, Myklebust CF, Sandset PM, Stavik B, Iversen N, Skretting G (2017)
Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1
Mol Cell Endocrinol, 443, 80-88
DOI 10.1016/j.mce.2017.01.016, PubMed 28088469

Tinholt M, Sandset PM, Mowinckel MC, Garred Ø, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
Determinants of acquired activated protein C resistance and D-dimer in breast cancer
Thromb Res, 145, 78-83
DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249

Ali HO, Arroyo AB, González-Conejero R, Stavik B, Iversen N, Sandset PM, Martínez C, Skretting G (2016)
The role of microRNA-27a/b and microRNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor α
J Thromb Haemost, 14 (6), 1226-37
DOI 10.1111/jth.13321, PubMed 26999003

Tinholt M, Sandset PM, Iversen N (2016)
Polymorphisms of the coagulation system and risk of cancer
Thromb Res, 140 Suppl 1, S49-54
DOI 10.1016/S0049-3848(16)30098-6, PubMed 27067978

Ali HO, Stavik B, Myklebust CF, Andersen E, Dahm AE, Iversen N, Sandset PM, Skretting G (2016)
Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5'-Flanking Region
PLoS One, 11 (3), e0152114
DOI 10.1371/journal.pone.0152114, PubMed 26999742

Cui XY, Tinholt M, Stavik B, Dahm AE, Kanse S, Jin Y, Seidl S, Sahlberg KK, Iversen N, Skretting G, Sandset PM (2016)
Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer
J Thromb Haemost, 14 (2), 387-96
DOI 10.1111/jth.13206, PubMed 26598923

Stavik B, Espada S, Cui XY, Iversen N, Holm S, Mowinkel MC, Halvorsen B, Skretting G, Sandset PM (2016)
EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells
Biochim Biophys Acta, 1862 (4), 670-678
DOI 10.1016/j.bbadis.2016.01.017, PubMed 26826018

Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N (2015)
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Breast Cancer Res, 17 (1), 44
DOI 10.1186/s13058-015-0548-5, PubMed 25882602

Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, Iversen N (2015)
Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells
PLoS One, 10 (1), e0117404
DOI 10.1371/journal.pone.0117404, PubMed 25617766

Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
BMC Cancer, 14, 845
DOI 10.1186/1471-2407-14-845, PubMed 25407022

Ali HO, Stavik B, Dørum E, Iversen N, Sandset PM, Skretting G (2014)
Oestrogen induced downregulation of TFPI expression is mediated by ERα
Thromb Res, 134 (1), 138-43
DOI 10.1016/j.thromres.2014.04.004, PubMed 24785473

Askautrud HA, Gjernes E, Gunnes G, Sletten M, Ross DT, Børresen-Dale AL, Iversen N, Tranulis MA, Frengen E (2014)
Global gene expression analysis reveals a link between NDRG1 and vesicle transport
PLoS One, 9 (1), e87268
DOI 10.1371/journal.pone.0087268, PubMed 24498060

Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM, Iversen N (2013)
TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity
J Hematol Oncol, 6, 5
DOI 10.1186/1756-8722-6-5, PubMed 23320987

Skretting G, Iversen N, Myklebust CF, Dahm AE, Sandset PM (2012)
Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF-κB and apoptosis mediated by a caspase-3 independent pathway
Mol Biol Rep, 39 (12), 10089-96
DOI 10.1007/s11033-012-1882-7, PubMed 22932941

Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, Sandset PM, Iversen N (2012)
TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells
PLoS One, 7 (10), e47184
DOI 10.1371/journal.pone.0047184, PubMed 23071754

Brandt C, Jakobsen AH, Adser H, Olesen J, Iversen N, Kristensen JM, Hojman P, Wojtaszewski JF, Hidalgo J, Pilegaard H (2011)
IL-6 regulates exercise and training-induced adaptations in subcutaneous adipose tissue in mice
Acta Physiol (Oxf), 205 (2), 224-35
DOI 10.1111/j.1748-1716.2011.02373.x, PubMed 21991887

Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset PM, Iversen N (2011)
Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility
BMC Cancer, 11, 357
DOI 10.1186/1471-2407-11-357, PubMed 21849050

Kostovski E, Dahm AE, Iversen N, Hjeltnes N, Østerud B, Sandset PM, Iversen PO (2011)
Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium
Blood Coagul Fibrinolysis, 22 (4), 254-9
DOI 10.1097/MBC.0b013e3283442ce2, PubMed 21297449

Tjeldhorn L, Iversen N, Sandvig K, Bergan J, Sandset PM, Skretting G (2011)
Protein C mutation (A267T) results in ER retention and unfolded protein response activation
PLoS One, 6 (8), e24009
DOI 10.1371/journal.pone.0024009, PubMed 21901152

Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N (2010)
Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells
Mol Carcinog, 49 (11), 951-63
DOI 10.1002/mc.20679, PubMed 20886581

Tjeldhorn L, Iversen N, Sandvig K, Bergan J, Sandset PM, Skretting G (2010)
Functional characterization of the protein C A267T mutation: evidence for impaired secretion due to defective intracellular transport
BMC Cell Biol, 11, 67
DOI 10.1186/1471-2121-11-67, PubMed 20815936

Skretting G, Stavik B, Landvik NE, Myklebust CF, Iversen N, Zienolddiny S, Sandset PM (2010)
Functional characterization of polymorphisms in the human TFPI gene
Biochem Biophys Res Commun, 397 (1), 106-11
DOI 10.1016/j.bbrc.2010.05.078, PubMed 20519147

Roslev P, Bukh AS, Iversen L, Sønderbo H, Iversen N (2010)
Application of mussels as biosamplers for characterization of faecal pollution in coastal recreational waters
Water Sci Technol, 62 (3), 586-93
DOI 10.2166/wst.2010.910, PubMed 20706005

Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO (2009)
Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas
Leuk Lymphoma, 50 (6), 998-1004
DOI 10.1080/10428190902889270, PubMed 19373600

Roslev P, Iversen L, Sønderbo HL, Iversen N, Bastholm S (2009)
Uptake and persistence of human associated Enterococcus in the mussel Mytilus edulis: relevance for faecal pollution source tracking
J Appl Microbiol, 107 (3), 944-53
DOI 10.1111/j.1365-2672.2009.04272.x, PubMed 19486428

Skretting G, Lien T, Sandset PM, Iversen N (2008)
Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability
Thromb Res, 123 (6), 851-5
DOI 10.1016/j.thromres.2008.09.003, PubMed 19007969

Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iversen PO (2008)
Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Leukemia, 23 (1), 162-9
DOI 10.1038/leu.2008.255, PubMed 18800145

Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM (2008)
Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
Thromb Haemost, 99 (6), 1040-8
DOI 10.1160/TH07-09-0541, PubMed 18521506

Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM (2006)
Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
BMC Cardiovasc Disord, 6, 40
DOI 10.1186/1471-2261-6-40, PubMed 17029634

Brodin E, Iversen N, Hansen JB (2006)
Impact of native VLDL on tissue factor pathway inhibitor in endothelial cells and interactions between TFPI and lipoprotein lipase
J Lab Clin Med, 147 (4), 167-73
DOI 10.1016/j.lab.2005.11.010, PubMed 16581344

Iversen N, Birkenes B, Torsdalen K, Djurovic S (2005)
Electroporation by nucleofector is the best nonviral transfection technique in human endothelial and smooth muscle cells
Genet Vaccines Ther, 3 (1), 2
DOI 10.1186/1479-0556-3-2, PubMed 15836781

Djurovic S, Iversen N, Jeansson S, Hoover F, Christensen G (2004)
Comparison of nonviral transfection and adeno-associated viral transduction on cardiomyocytes
Mol Biotechnol, 28 (1), 21-32
DOI 10.1385/MB:28:1:21, PubMed 15456960

Andresen MS, Iversen N, Abildgaard U (2002)
Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin
Thromb Res, 108 (5-6), 323-8
DOI 10.1016/s0049-3848(03)00067-7, PubMed 12676193

Iversen N, Brandtzaeg P, Sandset PM, Kierulf P, Abildgaard U (2002)
TFPI fractions in plasma from patients with systemic meningococcal disease
Thromb Res, 108 (5-6), 347-53
DOI 10.1016/s0049-3848(03)00065-3, PubMed 12676197

Iversen N, Lindahl AK, Abildgaard U (2002)
Elevated plasma levels of the factor Xa-TFPI complex in cancer patients
Thromb Res, 105 (1), 33-6
DOI 10.1016/s0049-3848(01)00404-2, PubMed 11864704

Iversen N, Strekerud FG, Abildgaard U (2000)
Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex
Blood Coagul Fibrinolysis, 11 (7), 591-8
DOI 10.1097/00001721-200010000-00002, PubMed 11085278

Iversen N, Lindahl AK, Abildgaard U (1998)
Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation
Br J Haematol, 102 (4), 889-95
DOI 10.1046/j.1365-2141.1998.00875.x, PubMed 9734635

Iversen N, Sandset PM, Abildgaard U, Torjesen PA (1996)
Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans
Thromb Res, 84 (4), 267-78
DOI 10.1016/s0049-3848(96)00186-7, PubMed 8948051

Other articles

Fiskvik H, Jacobsen AF, Iversen N, Henriksson CE, Jacobsen EM (2021)
Treatment of Homozygous Type II Antithrombin Heparin-Binding Site Deficiency in Pregnancy
Case Rep Obstet Gynecol, 2021, 4393821
DOI 10.1155/2021/4393821, PubMed 34513101

Chollet ME, Skarpen E, Iversen N, Sandset PM, Skretting G (2015)
The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells trough the GRASP55 pathway
Cell Biosci, 5, 57
DOI 10.1186/s13578-015-0048-4, PubMed 26457178

Book chapters

Iversen N, Strekerud FG, Abildgaard U (2000)
Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the factor X-TFPI complex
In Blood coagulation & fibrinolysis, Rapid Communications of Oxford Ltd., Oxford, UK, 11(2000)nr 7, s.591-598
BIBSYS 010781412

Theses

Iversen N (2004)
Studies on tissue factor pathway inhibitor in cell-cultures and in human blood plasma
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 232, 1 b. (flere pag.)
BIBSYS 051508737, ISBN 82-8080-132-4

Iversen N (1990)
Replikasjonstidspunkt for kromosom 11 genene Β-globin, insulin, THY1, APOA1 og APOC3 i HeLa celler
[N. Iversen], Oslo, 129 s.
BIBSYS 900773901